Psychedelic Therapeutics Clinical Trials Research Report 2024 Featuring Yale University, Johnson & Johnson, Shire Pharmaceuticals, Pfizer, Lykos, and UCB
13 sept. 2024 06h55 HE
|
Research and Markets
Dublin, Sept. 13, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trials: Psychedelic Therapeutics" report has been added to ResearchAndMarkets.com's offering.This report provides a review of global...
Virtual Clinical Trials Market Analysis and Forecasts, 2024-2032: Technological Innovation and Patient-Centric Models Spearhead Industry Evolution
02 juil. 2024 10h49 HE
|
Research and Markets
Dublin, July 02, 2024 (GLOBE NEWSWIRE) -- The "Virtual Clinical Trials Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and...
FDA Approves Phase II Clinical Trial for Ruxoprubart in ANCA Associated Vasculitis (AAV) – a Chronic Rare Disease in Nephrology
17 juin 2024 08h30 HE
|
NovelMed Therapeutics Inc
-- The United States FDA Clears Initiation of Efficacy Trial in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Patients A Phase II, Efficacy Trial in adult AAV patients has...
$43+ Billion Cell and Gene Therapy Clinical Trials Market Forecast, 2024-2034, by Therapy Type, Phase, Indication, and Region
05 juin 2024 03h41 HE
|
Research and Markets
Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Global Cell and Gene Therapy Clinical Trials Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's...
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
03 avr. 2024 07h00 HE
|
Arch Biopartners
TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an...
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
02 avr. 2024 07h26 HE
|
Arch Biopartners
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have...
Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight Report 2024: Combining CDC7 Kinase Inhibitors with Existing Cancer Therapies for Enhanced Efficacy
11 janv. 2024 05h28 HE
|
Research and Markets
Dublin, Jan. 11, 2024 (GLOBE NEWSWIRE) -- The "Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering. ...
USAN Approves Generic Name “Ruxoprubart” for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases
08 janv. 2024 08h30 HE
|
NovelMed Therapeutics Inc
The USAN Council has officially adopted "Ruxoprubart (Ruk”soe proo' bart)" as the generic name for NM8074, marking a significant milestone in the drug development process.Ruxoprubart is an...
Over 15 ATR Protein Inhibitors in Clinical Trials, Signifying Significant Advancements in Cancer Pharmaceutical Research
09 nov. 2023 06h43 HE
|
Research and Markets
Dublin, Nov. 09, 2023 (GLOBE NEWSWIRE) -- The "Global ATR Protein Inhibitors Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering. A...
World Edema Clinical Trials (Phase I, Phase II, Phase III, Phase IV) Market Size, Share & Trends Analysis Report 2023-2030
06 nov. 2023 06h23 HE
|
Research and Markets
Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Edema Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Participant (Pediatrics,...